Hispanics in Treatment: The Loxapine Experience

  • Evaristo Gomez
  • Madeline Gomez


Since 1975 the authors have been using Loxapine Succinate/ Hydrochloride [Loxitane (R)] in a variety of psychotic disorders such as Acute and Paranoid Schizophrenia, Bipolar Disorder, specifically the Manic Phase, in conjunction with Lithium Carbonate, Acute and Chronic Brain disorder and/or any psychotic disorder where loss of contact with reality (delusions and hallucinations) and agitation are cardinal symptoms.


Tardive Dyskinesia Psychotic Disorder Ergot Alkaloid Chronic Schizophrenia Hispanic Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Davis, J.M. and Casper, R.: Antipsychotic drugs; Clinical Pharmacology and therapeutic use. Drugs 14: 260–282. 1977.PubMedCrossRefGoogle Scholar
  2. 2.
    Ayd FJ Jr. Loxapine update: 1966–1976. Dis Nerv Syst 38:883–887, 1977.PubMedGoogle Scholar
  3. 3.
    Gomez, E., “Comparison of Loxapine, Chlorpromazine and Placebo,” Grand Rounds, George London Mem. Hosp. Chicago, IL, June 1976,Google Scholar
  4. 4.
    Gomez, E., “Loxapine vs. Haloperidol, Clinical Observations in Acute Schizophrenia,” paper read at Clinical Conference, George London Memorial Hospital, Chicago, IL, November 1976.Google Scholar
  5. 5.
    Arce, A., Torres-Matrullo, C, “Acculturation: Its Impact on Treatment Strategies,” paper read “The Hispanic American Symposium,” A.P.A. Annual Meeting, Atlanta, GA, May 1978.Google Scholar
  6. 6.
    Gomez, E., “Clinical Observations In The Treatment of Tardive Dyskinesia with Dihydrogenated Ergot Alkaloids (Hydergine), Preliminary Findings,” Psych. J. Univ. Ottawa, Vol. II, No. 2, July 1977.Google Scholar
  7. 7.
    Gomez, E., “The Chronic Patient, Patterns of Rehabilitation,” paper read to the Faculty Ottawa University — School of Medicine, Dept. of Psychiatry, Ottawa, Canada, March 1982.Google Scholar
  8. 8.
    Hollister, L.E.: Uses of Psychotherapeutic Drugs. Ann. Int. Med. 79:88–98, 1973.PubMedCrossRefGoogle Scholar
  9. 9.
    Tune, LE, McHugh PR, Coyle JT: Management of extrapyramidal side effects. induced by neuroleptics. Johns Hopkins Med J 148:149–153, 1981.PubMedGoogle Scholar
  10. 10.
    Cole, J. O.: Therapeutic approaches to tardive dyskinesia. Arch. Gen. Psychiat. 27:491–499, 1972.PubMedCrossRefGoogle Scholar
  11. 11.
    Weidley EF, Setler PE, Rush JA:Google Scholar
  12. 12.
    Clark ML, Paredes A. Costiloe JP, et al: Loxapine in newly admitted chronic schizophrenic patients. J Clin Pharmacol 15:286–292, 1975.PubMedCrossRefGoogle Scholar
  13. 13.
    Gomez, M., Gomez, E., “Hispanics in Treatment: The Amoxapine Experience,” paper read at the Symposium “The Treatment of Hispanic Patients in the U.S.A.” at the VII World Congress of Psychiatry, Vienna, Austria, July 198.Google Scholar

Copyright information

© Springer Science+Business Media New York 1985

Authors and Affiliations

  • Evaristo Gomez
    • 1
  • Madeline Gomez
    • 2
  1. 1.Attending Physician Ravenswood and Barclay HospitalsU. of I.ChicagoUSA
  2. 2.Ravenswood Hospital C.M.H.C.Univ. of IL.ChicagoUSA

Personalised recommendations